5th APV Winter Conference 2020  | KN 6795

Individualized Medicines − visions and challenges for all stakeholders in pharmaceutics 23.01. - 24.01.2020 | Innsbruck, Austria


Austria Trend Hotel Congress Innsbruck
Rennweg 12a
6020 Innsbruck

Kursprogramm zum Download


Individualized Medicine is a recent trend in pharmaceutical development, medical treatment and new drug applications. New active substances, including modified autologous cells obtained by Car-T technology, have received the market authorization by EMA and FDA quite recently. Significant progress in modern drug dosage forms and medical devices, including software applications, span a broad view on various treatment options by sophisticated future medicines. This is the 5th event within APV’s Winter Conference series in a row. Innovation speed and height is still there. Where are we today? Are we really prepared for the breakthrough of individualized medicines? The seminar reflects the most recent state-of-the-art in pharmaceutical development and manufacturing, indicate bright new ideas and future concepts without neglecting the constraints such as drug regulatory issues and economics. The seminar is highly recommended for pharmacists in community pharmacies, hospital pharmacies or pharmaceutical industry, other scientists or engineers operating in pharmaceutical development, manufacturing, business development and clinics.

This hot topic seminar, organized by APV’s Task Force “Individual Medicines”, is embedded in APV’s winter conference series. It will tackle obstacles such as biopharmaceutical and regulatory evaluations of flexible dosing systems, but offer some recent ideas and products to approach the future in oral medicines.


The seminar is highly recommended for pharmacists in community pharmacies, hospital pharmacies or industry, other scientists or engineers operating in pharmaceutical development, manufacturing, business development and clinics.

* Limited places for full time students available; written evidence must be submitted.


Prof. Dr. Jörg Breitkreutz, University of Duesseldorf, Germany

Jörg Breitkreutz is a pharmacist by training and finished his PhD in 1996 at the Institute for Pharmaceutical Technology and Biopharmaceutics in Münster under supervision of Prof. Gröning.

From 1996 to 1997 he joined Thiemann Arzneimittel GmbH in Waltrop, Germany, and from 1997 to 2004 the University of Münster to work on his habilitation on paediatric drug formulations.
In 2004 he became professor for pharmaceutical technology at the Heinrich-Heine-University in Düsseldorf, Germany.
Since 2010 he is the president of the International Association of Pharmaceutical Technology (APV).

His research focuses on paediatric drug formulations, orphan drugs and process analytical technologies.



Dr. Markus Dachtler, MD, DiHeSys Digital Health Systems GmbH

Dr. Markus Dachtler studied chemistry in Tübingen, Germany and economics in Neu-Ulm, Germany. In 2000 he finished his Ph.D. thesis in analytical chemistry in Tübingen dealing with direct LC-NMR-MS coupling analysis of biomedicals.

From 2000-2004 Dr. Markus Dachtler was employed as scientist at Unilever R&D, Vlaardingen, the Netherlands.
From 2004-2015 he joined ratiopharm (since 2010 within Teva group), Ulm, Germany and worked in different departments (Stability control, R&D Project Management, General Management).
In June 2015 Dr. Markus Dachtler acquired Gen-Plus GmbH & Co KG in Munich, Germany. Dr Dachtler is also co-founder of the company DiHeSys – Digital Health Systems. The company is a healthcare provider for personalized medication.

Dr. Dachtler gives regular lectures in the field of generics development and pharma business. He has authored more than 20 publications in international journals and also holds 1 patent.

In his scientific career he got several innovation awards and the Richard R. Ernst Prize in 1998.



Dr. Elke Sternberger-Rützel, Harro Höfliger, Germany

Elke Sternberger-Rützel studied pharmacy at the FU Berlin and Eberhard-Karls-Universität Tübingen until 1998. Thereafter she started 1998 to earned her doctorate in Pharmaceutical Technology at the Karl Ruprecht University Heidelberg. She is also a pharmacist specializing in pharmaceutical technology. After completing her doctorate, she worked in the pharmaceutical development department of Grünenthal GmbH (2002-2006) as laboratory manager for packaging development, stability studies and packaging of clinical test samples. Later in the R & D department of Catalent Pharma Solution (Schorndorf, Germany) (2006-2009) as a packaging developer with a focus on microdosing, as interim head of department and project manager. Subsequently, she was hired as Pharma Trendscout and Innovation Manager at Robert Bosch Gmbh Packaging Pharma (2009-2012). Since 2013 she has been working for Harro Höfliger GmbH as Head of Test Facilities within Pharma Services.




  Bis 15.12.2019 Vom 16.12.2019
Industry 1.290,00 € 1.490,00 €
Authority/University 645,00 € 745,00 €
Students 155,00 € 178,00 €
Alle Preise mehrwertsteuerfrei gemäß § 4,22 UStG



Dr. Martin Bornhöft
Tel.: +49 6131 9769-0
Fax: +49 6131 9769-69
E-Mail: apv@apv-mainz.de
www: https://www.apv-mainz.de/